Positive Results For New Oral Drug From Actelion

Author: Larry Husten
Date Published: June-2014
Source: Forbes

Actelion has announced positive top-line results for a phase III trial of a new oral drug for the treatment of pulmonary arterial hypertension (PAH). The drug, selexipag, is a first-in-class orally available selective prostacyclin IP receptor agonist. The pivotal, double-blind GRIPHON study was the largest outcome trial ever performed in PAH. 1,156 PAH patients were randomized to selexipag or placebo. The company said that trial had “met its primary efficacy endpoint with high statistical significance.” After followup of up to 4.3 years, selexipag reduced the risk of a morbidity or mortality event by 39% (p<0.0001).